
0:48
Single-speaker YouTube excerpt (Dr. Charles Mok) addressing circulating claims that semaglutide (GLP-1 agonists such as Wegovy/Ozempic) cause loss of lean muscle mass. The speaker notes that major trials reported ~15–17% body-weight loss over a year but did not comprehensively measure lean body mass, and that body-composition tools (DEXA, ultrasound, bioelectrical impedance) are the accepted methods for distinguishing fat vs. muscle loss. The speaker frames some of the claims as rumors spread by experts and community physicians.










